[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2002100473A1 - Tuteur coronarien et catheter d'administration - Google Patents

Tuteur coronarien et catheter d'administration Download PDF

Info

Publication number
WO2002100473A1
WO2002100473A1 PCT/AU2002/000745 AU0200745W WO02100473A1 WO 2002100473 A1 WO2002100473 A1 WO 2002100473A1 AU 0200745 W AU0200745 W AU 0200745W WO 02100473 A1 WO02100473 A1 WO 02100473A1
Authority
WO
WIPO (PCT)
Prior art keywords
stent
elongate body
delivery catheter
carrier means
ridges
Prior art date
Application number
PCT/AU2002/000745
Other languages
English (en)
Inventor
Graeme Cocks
Geoffrey H. White
Original Assignee
Graeme Cocks
White Geoffrey H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Graeme Cocks, White Geoffrey H filed Critical Graeme Cocks
Publication of WO2002100473A1 publication Critical patent/WO2002100473A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
    • A61F2230/0028—Shapes in the form of latin or greek characters
    • A61F2230/0054—V-shaped
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus

Definitions

  • the present invention relates to a stent for placement in a bodily vessel or cavity, a delivery catheter for the placement of a stent and a stent delivery system..
  • Occlusive diseases affecting the vasculature or other vessels are common. Such diseases include atherosclerosis which is characterised by a build up of plaque from cholesterol residues. The plaque build up subsequently thickens and hardens the arterial wall to create an arterial stenosis. The resultant narrowing of the artery has adverse effects on blood flow through the vessel.
  • stents may be inserted percutaneously through a distal and connecting vessel to that in which the stent is to be used.
  • the device may be inserted through the femoral artery in a catheter, where the device is intended to be used in the treatment of a stenotic lesion within the aorta.
  • the device may expand to a desirable size, and may extend above and below the lesion thereby bridging that lesion.
  • a procedure known as balloon angioplasty may also be used in the treatment of stenotic disease. This involves the delivery of a deflated balloon to the stenotic lesion. Once in place, the balloon is inflated to thereby break down the stenotic lesion.
  • the present invention aims to address the above problems of the prior art.
  • the present invention is a stent that is implantable within a vessel or cavity of a body, the stent including at least one carrier means to facilitate the delivery of a bioactive substance to a site of implantation of the stent.
  • the present invention is a delivery catheter for a stent said stent being implantable within a bodily vessel or cavity, the catheter including at least one carrier means to facilitate the delivery of a bioactive substance to a site of implantation of the stent.
  • the present invention is a stent delivery system including a delivery catheter extending from a proximal end to a distal end, and a stent positioned within the delivery catheter at a region adjacent the distal end of the catheter, the stent and/or catheter having at least one carrier means to facilitate the delivery of a bioactive substance to a site of implantation of the stent.
  • the stent typically comprises an elongate body made up of a series of unit cells, said elongate body extending from a proximal end to a distal end.
  • the carrier means of the stent may comprise one or a plurality of channels which extend in a longitudinal direction along a length of the elongate body of the stent.
  • the channels may be circumferentially arranged around the elongate body of the stent.
  • the channels are formed on an outer surface of the elongate body, as part of the stent body.
  • the channels may be formed separately of the stent body and connected to an outer surface of the stent body.
  • the channels preferably extend in a longitudinal direction for at least a portion of the length of the stent body and preferably along the entire length of the stent body.
  • the carrier means may be defined by one or a plurality of ridges which extend in a longitudinal direction along a length of the elongate body of the stent.
  • the ridges are preferably formed on an outer surface of the stent as part of the stent body.
  • the ridges may be formed separately of the stent body and connected to an outer surface of the stent body.
  • the ridges extend in a longitudinal direction along the entire length of the stent body.
  • the ridges of this embodiment when formed on or connected to, the outer surface of the stent body define a series of trough-like areas relative to said ridges on the surface of said stent. As discussed further below, the formation of such trough-like areas provides a carrier means for a bioactive substance.
  • the carrier means may be defined by a combination of both channels and ridges which extend in a longitudinal direction along at least part of the length of the elongate body of the stent.
  • the channels and ridges extend along the entire length of the elongate body of the stent.
  • the carrier means may comprise a series of depot members located along the length of the elongate body of the stent.
  • each depot member may comprise an indented area which may be filled with a bioactive agent.
  • the depot member may further include a cover member to retain the contents therein. The cover member may break down upon positioning of the stent in a target vessel thereby releasing the contents of the depot member to the surrounding environment.
  • the stent typically undergoes a change in state from a compressed state during introduction via an introducer catheter, to an expanded state upon deployment from said introducer catheter.
  • the introducer catheter typically comprises an elongate, substantially tubular body which extends from a proximal end to a distal end.
  • the stent of the present invention may be packaged within the introducer catheter at a region adjacent the distal end of the introducer catheter. When in use, the distal end of the introducer catheter is typically advanced through a vessel of the body to the target site of implantation of the stent.
  • the stent may be self-expandable upon deployment.
  • the stent may be maintained in its compressed state by the compressive force of the introducer catheter during insertion into a vessel of a subject.
  • the introducer catheter may be withdrawn thereby releasing the compressive force and allowing the stent to self-expand to its expanded state and into contact with the wall of the target vessel or a cavity.
  • the stent may be balloon expandable.
  • a balloon catheter may be positioned within the introducer catheter, said balloon catheter comprising an inflatable balloon which is positioned internal the stent body.
  • the introducer catheter may be relatively withdrawn and the balloon of the balloon catheter inflated such that it applies an outward force on the stent body thereby causing the stent body to move from its compressed state to its expanded state.
  • the outer surface of the stent body typically abuts with the wall of a target vessel or cavity thereby forming a good fit within said vessel or cavity.
  • the stent may be formed of a thin biocompatible material such as
  • NitinolTM or stainless steel. Other alloys such as tantalum or Elgiloy may be used.
  • the stent may self expand upon exposure to the surrounding body temperature at the site of implantation.
  • the stent body may include channels or ridges along at least part of its length both when the stent body is in its compressed state during introduction of the stent to a target site via an introducer catheter and when the stent body is in an expanded state upon deployment of the stent body from the introducer catheter and into a vessel of a subject.
  • the stent may include said channels or ridges on an outer surface of the stent body when in its compressed state only.
  • the outer circumference of the stent body is substantially cylindrical, that is, the channels and/or ridges either disappear or form only relatively small channels or ridges respectively in the surface of the expanded stent body.
  • This embodiment has the advantage that the outer surface of the expanded stent provides a good fit within a target vessel or cavity.
  • the bio-active substance is preferably added to the carrier means of the stent immediately prior to insertion of the stent into the body of the patient. This has the advantage that a surgeon may select a bioactive substance of choice for a patient prior to surgery.
  • the stent packaged at or adjacent a distal end of an introducer catheter it is envisaged that a surgeon may introduce the bioactive substance from the distal end of the introducer catheter and in manner such that the bioactive substance passes over the elongate body of the stent.
  • the bioactive substance may, however, also be introduced from the proximal end of the introducer catheter. Because the stent is compressed by the introducer catheter, the flow of bioactive substance over the stent body is limited to the carrier means of the stent.
  • the carrier means comprises one or a plurality of channels formed in the surface of the stent body, the bioactive substance passes along said channels, effectively coating the surface of the channels with bioactive substance.
  • the carrier means includes one or a plurality of ridges
  • said ridges typically abut with an internal wall of the introducer catheter when compressed by said introducer catheter thereby causing the remainder of the stent body to form trough-like areas, that is, slightly spaced from the internal wall of the introducer catheter.
  • the bioactive substance therefore passes through said spaced areas effectively coating a percentage of the surface of the stent body with bioactive substance.
  • the bioactive substance may, however, be added to the carrier means of the stent during or subsequent to manufacture of the stent.
  • the bioactive substance may be stored in the carrier means of the prepackaged stent of the stent delivery means of the third aspect of the present invention.
  • Different packages may have different bioactive substances or dosages of a particular bioactive substance. This provides the physician with a range of pre-packaged stent options without the need to separately order or draw up a bioactive substance for use in a surgical procedure.
  • the carrier means may not retain all of the bioactive substance added to the carrier means. If some of the bioactive substance is not retained, this is not presently envisaged to constitute a problem as potentially only a relatively small quantity of bioactive substance need reach the implantation site (depending upon the substance and its concentration). It is, however, preferred that the bioactive substance coat at least a portion and preferably a substantial area of the outer surface of the stent either prior to or during its implantation.
  • the channels or the trough-like areas defined by the ridges of the carrier means may either be open to the surrounding environment or covered by a protection member.
  • the carrier means comprises a channel or a plurality of channels, that the channel has a cover which retains the bioactive substance within the channel(s) during delivery of the stent but which breaks down or degrades upon deployment of the stent to a target site of implantation,
  • the carrier means of the stent may be formed during the manufacture of the stent of the invention.
  • the stent body is made from a shape memory material such as NitinolTM
  • a cylinder of NitinolTM is taken to a desired temperature to allow the material to achieve a "memory" of a certain configuration.
  • the carrier means is a channel which longitudinally extends along the stent body as described above, when the cylinder of NitinolTM is taken to this temperature, a template is used to push the area of the cylinder which is to become the channel inwardly relative to the remainder of the cylindrical tubular body.
  • the temperature at which the NitinolTM takes on its "memorised" shape is room temperature.
  • the stent may resume the configuration of a cylindrical tube thereby providing a good fit in vessel or cavity.
  • a pre-formed tubular body is laser cut to a desired shape including either or both channels or ridges.
  • the delivery catheter of the second aspect may comprise a substantially tubular, elongate body which extends from a first end to a second end and which is adapted to receive a stent.
  • the carrier means of the delivery catheter may comprise one or a plurality of channels on an inner wall of the delivery catheter.
  • the carrier means may be defined by one or a plurality of ridges on the inner wall of the delivery catheter.
  • the delivery catheter comprises both channels and ridges on said inner wall.
  • the channels and/or ridges extend in a longitudinal direction along the elongate body of the delivery catheter and extend a distance which is substantially equal to the length of a stent to be placed or pre-packaged within the elongate body of the delivery catheter.
  • the channels and/or ridges typically define areas wherein the stent is substantially spaced from the inner wall of the delivery catheter.
  • the bioactive substance may then be introduced into the delivery catheter such that said spaced areas of the stent are coated with bioactive substance.
  • the delivery catheter may be formed from any suitable plastics material, particularly, a biocompatible plastic.
  • the bioactive substance may include a pharmaceutical substance.
  • the bioactive substance may also include a radioactive substance.
  • the bioactive substance can be a substance which stimulates fibrin or cellular ingrowth into the stent from the surrounding tissue. Such ingrowth further secures the stent within the vessel wall.
  • a material which increases tissue ingrowth into the tubular graft bodies is polyurethane.
  • a polyurethane/polycarbonate composite may be used to enhance cellular ingrowth.
  • bioactive substances which may be carried by the stent or delivery catheter of the present invention include, but are not limited to, anti- sense antibodies, immune suppressants such as serolimus and chemotherapeutic agents such as taxol and rabamycin Brief Description of the drawings
  • Figure 1 is a perspective view of a stent according to the present invention.
  • Figure 2 is a further perspective view of a stent according to the present invention
  • Figure 3 is a perspective view of one embodiment of the stent of the present invention
  • Figure 4 is a perspective view of an embodiment of a delivery catheter according to the present invention.
  • Figure 5 is a perspective view of another embodiment of a delivery catheter according to the present invention. Preferred Mode of Carrying Out the Invention
  • the stent of the present invention is generally depicted as 10 in accompanying Figures 1 to 3.
  • the stent 10 comprises an elongate body 11 which extends from a proximal end 12 to a distal end 13.
  • the stent 10 further includes a carrier means 14 to facilitate the delivery of one or more bioactive substances to a site of implantation of the stent 10.
  • the carrier means 14 comprises longitudinal channels 15 formed in the outer surface 17 of the stent 10 and longitudinal ridges 16 formed in said outer surface 17 of the stent 10. While not depicted, the carrier means of the stent of the present invention may comprise either channels 15 or ridges 16 rather than a combination of the two.
  • the channels 15 and ridges 16 are shown as extending longitudinally along the entire length of the elongate body 11, from proximal end 12 to distal end 13.
  • the elongate body 11 is made up of a series of unit cells 18.
  • the channels 15 and ridges 16 of the embodiments depicted in Figures 1 and 2 are formed from the unit cells 18 of the elongate body 11, that is, the channels 15 and ridges 16 are integral the elongate body
  • the channels 15 and ridges 16 are not formed from the unit cells 18 and, instead are solid in structure.
  • the channels 15 and ridges 16 of this embodiment while typically made from the material of the elongate body 11 are formed as a solid structure during the manufacture of the stent 10.
  • the ridges 16, when formed on or connected to, the outer surface 17 of the stent 10 define a series of trough-like areas 19 relative to said ridges 16. As discussed further below, the formation of such trough-like areas 19 provides a carrier means for a bioactive substance.
  • the stent 10 typically undergoes a change in state from a compressed state (not shown) during introduction via an introducer catheter (not shown), to an expanded state ( Figures 1 to 3) upon deployment from said introducer catheter.
  • the introducer catheter is typically an elongate, substantially tubular structure which extends from a proximal end to a distal end.
  • the stent of the present invention may be packaged within the introducer catheter at a region adjacent the distal end of the delivery catheter. When in use, the distal end of the introducer catheter is typically advanced through a vessel of the body to the target site of implantation of the stent.
  • the stent 10 is self-expandable upon deployment.
  • the stent is maintained in its compressed state by the compressive force of the introducer catheter during insertion into a vessel of a subject.
  • the introducer catheter may be withdrawn thereby releasing the compressive force and allowing the stent 10 to self-expand to its expanded state and into contact with the wall of a target vessel or a cavity.
  • the stent is balloon expandable.
  • a balloon catheter (not shown) is positioned within the introducer catheter, said balloon catheter comprising an inflatable balloon which is positioned internal the elongate body 11.
  • the introducer catheter is relatively withdrawn and the balloon of the balloon catheter inflated such that it applies an outward force on the elongate body 11 of the stent 10 thereby causing the stent 10 to move from its compressed state to its expanded state.
  • the outer surface 17 of the stent body abuts with the wall of a target vessel or cavity thereby forming a good fit within said vessel or cavity.
  • the stent 10 depicted in Figures 1 to 3 is made from a shape memory material such as NitinolTM.
  • the material of the stent 10 has a "memory" such that said stent 10 self expands upon exposure to its surrounding temperature at the site of implantation.
  • the stent 10 of this embodiment may also include a "memory" of other configurations.
  • the carrier means 14 of the stent 10 can be formed during the manufacture of the stent 10. For example, a cylinder of NitinolTM is taken to a desired temperature to allow the material to achieve a "memory" of a certain configuration. If the carrier means 14 is a channel 15 which longitudinally extends along the elongate body 11 as described above, when the cylinder of NitinolTM is held at the "memory" temperature, a template is used to push the area of the cylinder which is to become the channel inwardly relative to the remainder of the cylindrical tubular body. When the stent 10 is exposed to this "memory" temperature, channels will form in the elongate body 11.
  • the stent 10 only includes said channels 15 when in its compressed state, in which case, the temperature upon which the NitinolTM 1 takes on its "memorised" shape is room temperature.
  • the bioactive substance may therefore by introduced into the channels by a surgeon prior to surgery.
  • the stent may resume the configuration of a cylindrical tube (said channels substantially disappearing) thereby providing a good fit in vessel or cavity.
  • the bio-active substance is added to the carrier means of the stent immediately prior to insertion of the stent 10 into the body of the patient. This has the advantage that a surgeon may select a bioactive substance of choice for a patient prior to surgery.
  • the surgeon may syringe the bioactive substance into the distal end of the introducer catheter and in manner such that the bioactive substance passes over the elongate body 11 of the stent 10.
  • the bioactive substance may, however, also be introduced from the proximal end of the introducer catheter. Because the outer surface 17 of the stent 10 abuts with an inner surface of the introducer catheter, when the bioactive substance is syringed into the introducer catheter, the flow of bioactive substance over the elongate body 11 is limited to the carrier means 14 of the stent 10, that is, the channels 15 or the trough-like areas 19 which are defined by ridges 16. Where the carrier means 14 comprises channels 15, the bioactive substance passes along said channels 15, effectively coating the surface of the channels 15 with bioactive substance.
  • the carrier means comprises ridges 16, the ridges 16 abut with an internal wall of the introducer catheter thereby causing the remainder of the stent body to form trough-like areas 19, that is, slightly spaced from the internal wall of the introducer catheter.
  • the bioactive substance therefore passes over said trough-like areas 19, effectively coating a percentage of the outer surface 17 of the elongate body 11 with bioactive substance.
  • the delivery catheter of the second aspect of the present invention is generally depicted as 30 in Figures 4 and 5.
  • the delivery catheter 30 comprises a substantially tubular, elongate body 31 which extends from a first end 32 to a second end 33 and which is adapted to receive a stent (shown in phantom).
  • the delivery catheter further includes a carrier means 34 to facilitate the delivery of a bioactive substance to a site of implantation of said stent.
  • the carrier means 34 comprises longitudinal channels 35 formed in an inner wall 36 of the delivery catheter 30.
  • the carrier means 34 is defined by longitudinal ridges 37 formed along the inner wall 36 of the delivery catheter 30. While not depicted, the carrier means 34 may be defined by both channels 35 and ridges 37 formed in the inner wall 36 of the delivery catheter 30.
  • the channels 35 and/or ridges 37 extend a distance which is substantially equal to the length of the stent to be placed or pre-packaged in the delivery catheter.
  • the channels and/or ridges define areas 38 wherein the stent is substantially spaced from the inner wall 36 of the delivery catheter 30.
  • the bioactive substance is introduced into the delivery catheter (shown by arrows A) such that it substantially coats the stent at said spaced areas 38.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne un tuteur coronarien (10) et un cathéter d'introduction (30) comportant un organe support (14) destiné à administrer une substance bioactive sur le site d'implantation du tuteur coronarien (10). Ledit organe support (14) comporte des canaux (15) et/ou des arêtes (16) s'étendant longitudinalement le long du tuteur coronarien (10) et définissant des zones espacées de la paroi interne du cathéter d'introduction, lesdites zones étant revêtues de la substance bioactive lors du passage de celle-ci dans le cathéter d'introduction. Dans un autre mode de réalisation, l'organe support (14) peut être défini par le cathéter d'introduction (30) pouvant comporter les canaux (35) et/ou arêtes (37) sur sa paroi interne (36).
PCT/AU2002/000745 2001-06-08 2002-06-07 Tuteur coronarien et catheter d'administration WO2002100473A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR5602 2001-06-08
AUPR5602A AUPR560201A0 (en) 2001-06-08 2001-06-08 Stent

Publications (1)

Publication Number Publication Date
WO2002100473A1 true WO2002100473A1 (fr) 2002-12-19

Family

ID=3829576

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2002/000745 WO2002100473A1 (fr) 2001-06-08 2002-06-07 Tuteur coronarien et catheter d'administration

Country Status (2)

Country Link
AU (1) AUPR560201A0 (fr)
WO (1) WO2002100473A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2858207A1 (fr) * 2003-07-28 2005-02-04 Perouse Laboratoires Endoprothese a liberation controlee de produit medicamenteux
GB2469297A (en) * 2009-04-07 2010-10-13 Cook Inc A sheath with longitudinal channels on its inner wall
CN104717941A (zh) * 2013-01-30 2015-06-17 泰尔茂株式会社 生物体管腔用治疗系统及支架
CN107411844A (zh) * 2016-09-14 2017-12-01 四川蓝光英诺生物科技股份有限公司 管腔组织构建体及其制备方法、制备装置
GB2598271A (en) * 2020-02-18 2022-03-02 Wai Yin Lau Ernest A scaffold for a tube

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023228A1 (fr) * 1996-11-25 1998-06-04 Alza Corporation Stent destine a l'administration dirigee de medicaments
EP0920882A2 (fr) * 1997-12-04 1999-06-09 Schneider Inc. Cathéter à ballonet pour dilatation et apport de médicament et cathéter pour placer une prothèse à remplacement rapide
EP0950386A2 (fr) * 1998-04-16 1999-10-20 Cordis Corporation Stent permettant l'administration locale de rapamycine
WO2000038590A1 (fr) * 1998-12-23 2000-07-06 Stephen George Edward Barker Stent endoluminal
WO2000072907A1 (fr) * 1999-05-28 2000-12-07 Precision Vascular Systems, Inc. Appareil pour liberer des fluides dans des vaisseaux sanguins, des cavites du corps et similaire

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023228A1 (fr) * 1996-11-25 1998-06-04 Alza Corporation Stent destine a l'administration dirigee de medicaments
EP0920882A2 (fr) * 1997-12-04 1999-06-09 Schneider Inc. Cathéter à ballonet pour dilatation et apport de médicament et cathéter pour placer une prothèse à remplacement rapide
EP0950386A2 (fr) * 1998-04-16 1999-10-20 Cordis Corporation Stent permettant l'administration locale de rapamycine
WO2000038590A1 (fr) * 1998-12-23 2000-07-06 Stephen George Edward Barker Stent endoluminal
WO2000072907A1 (fr) * 1999-05-28 2000-12-07 Precision Vascular Systems, Inc. Appareil pour liberer des fluides dans des vaisseaux sanguins, des cavites du corps et similaire

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2858207A1 (fr) * 2003-07-28 2005-02-04 Perouse Laboratoires Endoprothese a liberation controlee de produit medicamenteux
GB2469297A (en) * 2009-04-07 2010-10-13 Cook Inc A sheath with longitudinal channels on its inner wall
GB2469297B (en) * 2009-04-07 2011-05-25 Cook Inc Introducer assembly and implantable medical device
US9724220B2 (en) 2009-04-07 2017-08-08 Cook Medical Technologies Llc Introducer assembly and implantable medical device
CN104717941A (zh) * 2013-01-30 2015-06-17 泰尔茂株式会社 生物体管腔用治疗系统及支架
EP2952160A4 (fr) * 2013-01-30 2016-08-17 Terumo Corp Système de traitement de lumière d'organisme, et endoprothèse
CN104717941B (zh) * 2013-01-30 2019-05-17 泰尔茂株式会社 生物体管腔用治疗系统及支架
CN107411844A (zh) * 2016-09-14 2017-12-01 四川蓝光英诺生物科技股份有限公司 管腔组织构建体及其制备方法、制备装置
GB2598271A (en) * 2020-02-18 2022-03-02 Wai Yin Lau Ernest A scaffold for a tube
GB2598271B (en) * 2020-02-18 2024-03-06 Wai Yin Lau Ernest A scaffold for a tube

Also Published As

Publication number Publication date
AUPR560201A0 (en) 2001-07-12

Similar Documents

Publication Publication Date Title
EP3245985B1 (fr) Système de délivrance de dispositif médical implantable
JP2940859B2 (ja) 脈管内ステント用形状記憶ロック機構
EP1791494B1 (fr) Système de mise en place de stent
US7955371B2 (en) System and method for stent deployment and infusion of a therapeutic agent into tissue adjacent to the stent ends
US6629992B2 (en) Sheath for self-expanding stent
AU749285B2 (en) Non-thrombogenic stent jacket
JP4651781B2 (ja) 自己膨張ステントデリバリー装置
EP1517653B1 (fr) Dispositifs de traitement d'anevrismes
US20050049678A1 (en) Stent
US20060015170A1 (en) Contrast coated stent and method of fabrication
US20050278011A1 (en) Stent delivery system
US20100241069A1 (en) Ostial lesion stent delivery system
JP2008507349A (ja) バルーンによる拡張が可能で変形回復性能を有するステント装置
JP2005511140A (ja) 網目状プロテーゼを送るための装置と方法
JP2004522494A6 (ja) ステント内再狭窄のためのステント
JP2004522494A (ja) ステント内再狭窄のためのステント
US20050004647A1 (en) Hybrid stent apparatus
JP2005527276A (ja) 保護組立体を有する被覆ステント及びその使用方法
WO2004021929A1 (fr) Systeme de stent modulaire et dispositif de mise en place
WO2002100473A1 (fr) Tuteur coronarien et catheter d'administration
US6447521B1 (en) Foamed inner member cover stent retention and method of use
EP1493401B1 (fr) Dispositif d'extenseur intravasculaire hybride
AU780149B2 (en) Non-thrombogenic stent jacket
WO2002007650A1 (fr) Stent amovible
IE20010685A1 (en) A removable stent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP